Incyte logo

INCY - Incyte News Story

$80.5 -0.8  -1.0%

Last Trade - 2:46pm

Sector
Healthcare
Size
Large Cap
Market Cap £12.86bn
Enterprise Value £11.47bn
Revenue £1.94bn
Position in Universe 648th / 6849

BRIEF-Lilly And Incyte Communicate Review Extension Of Supplemental NDA For Baricitinib

Tue 6th April, 2021 9:49pm
April 6 (Reuters) - Incyte Corp  INCY.O :
    * LILLY AND INCYTE COMMUNICATE REVIEW EXTENSION OF
SUPPLEMENTAL
NEW DRUG APPLICATION FOR BARICITINIB FOR THE TREATMENT OF
MODERATE TO SEVERE ATOPIC DERMATITIS
    * INCYTE CORP - PRESCRIPTION DRUG USER FEE ACT (PDUFA)
ACTION DATE
HAS BEEN EXTENDED THREE MONTHS TO EARLY Q3 2021.
    * INCYTE CORP - FDA EXTENDED ACTION DATE TO ALLOW TIME TO
REVIEW
ADDITIONAL DATA ANALYSES SUBMITTED BY LILLY IN RESPONSE TO
RECENT INFORMATION REQUESTS
    * INCYTE CORP - EXTENSION DOES NOT AFFECT LILLY'S
PREVIOUSLY-ISSUED FINANCIAL GUIDANCE FOR 2021

Source text for Eikon:  ID:nPn3v4jWsa 
Further company coverage:  INCY.O 

 ((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.